DRAGARWQBSEDr Agarwals Eye Hospital Ltd-$MediumNeutral
Announced Mon, 1 Jun · 13:11 IST

Notice convening the meeting of the Secured Creditors of the Company pursuant to the order of the Hon''ble NCLT, Chennai Bench.

Nclt Scheme FiledListed Co AcquisitionStrategic Transactions View source PDF

DRAGARWQ · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reaction · full curve 14 horizons · vs prior close
-0.9%1-day move
₹5080.00
prior close
₹5020.00
base price
In-mkt
timing
5m10m15m30m1D2D3D4D5D7D15D1M2M3M
+0.0+0.5+0.3+0.3-0.9+2.4-0.0-0.5-2.3-2.8-1.8-1.6
Up moveDown movePending
AI summary

Dr. Agarwal's Eye Hospital Limited (AEHL) is convening a meeting of its Secured Creditors on July 02, 2026 at 10:30 A.M. in Chennai, as directed by the NCLT Chennai Bench, to consider and approve a Scheme of Amalgamation with its parent company Dr. Agarwal's Health Care Limited (AHCL), which currently holds a 72.67% stake in AEHL. Under the scheme, AEHL (the Transferor Company, listed on BSE with ~63 eye care facilities) will merge into AHCL (the Transferee Company, listed on BSE and NSE with 288 facilities in India and 19 in Africa), consolidating both eye care businesses into a single entity. The company has engaged NSDL for e-voting (from June 07 to July 01, 2026), and the scheme has already received no-objection observations from NSE (Feb 16, 2026) and BSE (Feb 17, 2026). The merger is expected to be EPS accretive from the first year of implementation, with share valuation done by PwC and Bansi S. Mehta Valuers, and fairness opinions from Kotak Mahindra Capital and Motilal Oswal.

Likely market impact

This is a procedural NCLT step for the secured creditors to vote on the already-board-approved amalgamation. If approved, AEHL shareholders and the business will merge into the larger AHCL entity, potentially simplifying the group structure and improving operational efficiency. Short-term impact on stock may be limited as this is a creditor approval step, but successful merger could be EPS accretive.